“Smart drug” headlines lump together three very different prescriptions. Provigil (modafinil) and Nuvigil (armodafinil) are labeled to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea or shift work disorder. Adderall is an amphetamine labeled for ADHD and narcolepsy. The labels do not describe any of them as a way to sharpen thinking in someone who is simply tired or busy.
If you work nights or rotating shifts and heard about modafinil: the label covers shift work disorder, a diagnosed condition, and it is a Schedule IV controlled substance with a serious-rash warning. If you are a student or professional curious about “focus” drugs: none of these labels includes cognitive enhancement in healthy people, and Adderall carries a boxed warning for abuse, misuse and addiction.
Most of the confusion comes from treating “makes you alert” as one category. Regulators do not. A drug that helps a person with narcolepsy stay awake and a drug that treats ADHD are approved on different evidence, for different people, with different risk profiles. Reading the labels side by side shows how far apart they are.
Labels at a glance
| Provigil (modafinil) | Nuvigil (armodafinil) | Adderall (mixed amphetamine salts) | |
|---|---|---|---|
| FDA-labeled use | Improve wakefulness in adults with excessive sleepiness from narcolepsy, OSA or shift work disorder | Same three conditions | ADHD and narcolepsy |
| Drug relationship | 1:1 racemic mixture of R- and S-enantiomers | The R-enantiomer of modafinil | d- and l-amphetamine salts in a 3:1 ratio |
| Federal schedule | C-IV | C-IV | C-II |
| Headline warning | Serious rash including Stevens-Johnson syndrome; psychiatric symptoms; angioedema | Serious dermatologic reactions, DRESS, angioedema | Boxed warning: high potential for abuse and misuse, which can lead to substance use disorder including addiction; overdose and death |
| Contraception note | Effectiveness of steroidal contraceptives may be reduced during use and for one month after stopping | Same | No contraception interaction in the sections reviewed |
| Typical question it answers | Does my sleepiness have a treatable cause that this fits? | Same, with a different molecule | Does my attention problem meet an ADHD evaluation? |
Sources are the current Provigil, Nuvigil and Adderall labels on DailyMed; the Adderall entry we used is dated June 18, 2024.
Provigil vs. Nuvigil
These two are close relatives. The Provigil label describes modafinil as a racemic compound and says the half-life of R-modafinil is about three times that of S-modafinil, with total exposure to R-modafinil at steady state about three times that of S. Nuvigil contains armodafinil, the R-enantiomer, and its label describes the same three indications. Both labels contraindicate use in people with known hypersensitivity to modafinil or armodafinil and both state that in obstructive sleep apnea the drug treats excessive sleepiness, not the underlying obstruction. If CPAP is the treatment of choice, the labels say a maximal effort to treat with CPAP should be made first and continue.
Which one a prescriber chooses is usually about the individual response, timing and coverage rather than a categorical advantage; we did not find head-to-head trial data in the sources we opened. See modafinil and wakefulness: uses, risks and sleep debt for the broader safety picture.
The rash warning
Both wakefulness-drug labels devote a section to serious rash. The Provigil label says serious rash requiring hospitalization and discontinuation has been reported; in clinical trials the incidence of rash leading to discontinuation was about 0.8% (13 per 1,585) in pediatric patients younger than 17, and rare cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS have been reported in adults and children after approval. It says there are no factors known to predict who will develop a serious rash, that nearly all serious cases occurred within 1 to 5 weeks of starting but isolated cases occurred later, and that the drug should be discontinued at the first sign of rash unless the rash is clearly not drug-related. The Nuvigil label adds mouth sores, blistering or ulceration to the signs that call for stopping. Call the prescriber promptly for any new rash, fever with rash, facial swelling or mouth sores; our page on modafinil and birth control covers the contraception issue noted in the table.
Both Provigil and Nuvigil are Schedule IV controlled substances, and the Provigil label reports that modafinil produced psychoactive and euphoric effects, with mood, perception and thinking changes typical of other CNS stimulants, in a study of people experienced with drugs of abuse. Adderall is Schedule II, the more restrictive category, and carries the boxed warning. Schedules describe legal handling; they do not tell you which drug is safer for a given person.
Adderall is a different kind of drug
The Adderall label lists ADHD and narcolepsy as its indications and describes the product as a CNS stimulant whose mode of action in ADHD is not known; amphetamines are thought to block reuptake of norepinephrine and dopamine and increase their release. Its boxed warning states that Adderall has a high potential for abuse and misuse, which can lead to substance use disorder, including addiction, and that misuse can result in overdose and death. The label advises assessing each patient’s risk before prescribing, storing the medicine safely (preferably locked) and not giving it to anyone else. It also reports sudden death in patients with structural cardiac abnormalities or serious cardiac disease, and peripheral vasculopathy including Raynaud’s phenomenon. The half-lives in the label are about 9.8 to 11 hours for d-amphetamine and 11.5 to 13.8 hours for l-amphetamine.
That profile explains why an ADHD evaluation is a real assessment and not a prescription for alertness. Our guide to adult ADHD evaluation describes what that involves.
What about the “smart drug” idea?
Search interest in “Provigil vs Adderall” often comes from students and professionals comparing study aids. The labels do not support that framing. Modafinil and armodafinil are indicated to improve wakefulness in adults with excessive sleepiness from three named conditions; Adderall is indicated for ADHD and narcolepsy. None of the three labels we read includes boosting cognition in people without those conditions, and we found no regulator source we could cite that says the drugs do that safely. Using someone else’s prescription or buying pills online adds legal and quality problems: FDA warns about counterfeit and unapproved products sold online, and our guide to generic medicines and online pharmacy safety covers how to check a pharmacy. The better first question for someone who is constantly tired is why. Sleep debt, untreated sleep apnea, depression, thyroid problems and medicines can all cause it; excessive daytime sleepiness lists common causes.
Mood, sleep and heart: what the labels add
The Provigil label has a psychiatric warning section describing anxiety and other psychiatric symptoms that led to discontinuation in clinical trials and were reported more often than with placebo, and a cardiovascular section noting that chest pain, palpitations, dyspnea and transient ischemic T-wave changes occurred in a few subjects with mitral valve prolapse or left ventricular hypertrophy, with increased monitoring suggested for people with known cardiovascular disease. Those are label statements about monitoring, not a prediction for any one person. Adderall’s label has its own cautions: CNS stimulants may exacerbate behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder and may induce a manic or mixed episode, and sudden death has been reported in patients with structural cardiac abnormalities. A prescriber needs your cardiac history, your mental health history and any substance use before choosing among the three.
Abuse potential, in the label’s own words
The Provigil label’s abuse section reports that the abuse potential of modafinil at 200, 400 and 800 mg was assessed relative to methylphenidate in an inpatient study of people experienced with drugs of abuse, and that modafinil produced psychoactive and euphoric effects and feelings consistent with other scheduled CNS stimulants. Because Adderall is classed as Schedule II with a boxed warning, the expectation of careful follow-up is stronger. For all three, a plan for follow-up, storage and not sharing is part of safe use, not an accusation.
If you work nights
Shift work disorder is a recognized condition, not a character flaw, and the labels treat the medicine as one piece of a plan. A prescriber will typically want to know your actual sleep opportunity, whether you have sleep apnea, and what else you take. Before asking about medication it is worth building the basics described in our night-shift sleep plan: protected sleep, light exposure timing and days-off strategy.
- Ask whether a sleep study is appropriate to rule out apnea first. The labels say that for OSA the medicine treats sleepiness, not the cause.
- Bring a log of sleep and work times for two weeks.
- Mention any history of heart disease, psychiatric symptoms or substance use. The Provigil label lists psychiatric symptoms and cardiovascular events among its warnings.
- If you use hormonal contraception, ask about the label’s advice for an additional method during treatment and for one month afterward.
Questions for the visit
- What is the diagnosis that this medicine would treat, and how was it confirmed?
- Are we treating sleepiness with a plan for the cause (sleep apnea, schedule, depression)?
- What rash or mood changes should make me call immediately?
- How do my other medicines and my contraception interact with this drug?
- How long will we try it, and how will we judge whether it helps?
Sources
Evidence checked October 30, 2026. General information only; these are controlled substances that require a prescriber’s evaluation.